2Chen HS, Zhang XQ. Antiviral Drug and Method(抗病毒药物与方法)[M].Beijing: Chemical Industry Press, 2006.
3Hsieh YC, Wu TZ, Liu DE et al. Influenza pandemics: past,present and future [J]. J Formosan Med Assoc, 2006, 105: 1-6.
4LiuLX WangY.Advances of rabivirin clinical study .现代中西医结合杂志,2008,17:5542-5543.
5Knipe DM, Howley PM, Martin MA, et al. Fields Virology. 5th ed [M]. Lippincott Williams & Wilkins, 2007: 1697- 1701.
6Arino J, Bowman CS, Moghadas SM. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use [J]. BMC Infect Dis, 2009, 9: 8.
7Monto AS. Antivirals and influenza: frequency of resistance [J]. Pediatr Infect Dis J. 2008, 27: S110-112.
8Leyssen P, De Clercq E, Neyts J. Molecular strategies to inhibit the replication of RNA viruses [J]. Antivirad Res, 2008, 78: 9-25.
9Sugrue RJ, Tan BH, Yeo DS, et al. Antiviral drugs for the control of pandemic influenza virus [J]. Ann Acad Med Singapore, 2008, 37: 518-524.
10Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza [J]. N Engl J Med, 2009, 361: 1713-1714.
